New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy
Open Access
- 5 January 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1026377
Abstract
Over the last 20 years, granulocyte colony-stimulating factors (G-CSFs) have become the major therapeutic option for the treatment of patients with neutropenia. Most of the current G-CSFs require daily injections, which are inconvenient and expensive for patients. Increased understanding of G-CSFs’ structure, expression, and mechanism of clearance has been very instrumental in the development of new generations of long-acting G-CSFs with improved efficacy. Several approaches to reducing G-CSF clearance via conjugation techniques have been investigated. PEGylation, glycosylation, polysialylation, or conjugation with immunoglobulins or albumins have successfully increased G-CSFs’ half-lives. Pegfilgrastim (Neulasta) has been successfully approved and marketed for the treatment of patients with neutropenia. The rapidly expanding market for G-CSFs has increased demand for G-CSF biosimilars. Therefore, the importance of this review is to highlight the principle, elimination’s route, half-life, clearance, safety, benefits, and limitations of different strategies and techniques used to increase the half-life of biotherapeutic G-CSFs. Understanding these strategies will allow for a new treatment with more competitive manufacturing and lower unit costs compared with that of Neulasta.Keywords
This publication has 109 references indexed in Scilit:
- Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapyBMC Cancer, 2013
- Biophysical Characterization of Met-G-CSF: Effects of Different Site-Specific Mono-Pegylations on Protein Stability and AggregationPLOS ONE, 2012
- Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisBMC Cancer, 2011
- Delivery of Therapeutic ProteinsJournal of Pharmaceutical Sciences, 2010
- Centralized Modularity of N-Linked Glycosylation Pathways in Mammalian CellsPLOS ONE, 2009
- Effects of glycosylation on the stability of protein pharmaceuticalsJournal of Pharmaceutical Sciences, 2009
- Efficacy of native and hyperglycosylated follicle-stimulating hormone analogs for promoting fertility in female miceFertility and Sterility, 2009
- Sialic acids in human health and diseaseTrends in Molecular Medicine, 2008
- Albumin Binding to FcRn: Distinct from the FcRn−IgG InteractionBiochemistry, 2006
- Enhancement of therapeutic protein in vivo activities through glycoengineeringNature Biotechnology, 2003